CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Stock Has Average Price Target of $10.44

CAMP4 Therapeutics Corporation (NASDAQ:CAMP) has been given an average rating of “Moderate Buy” by the eleven analysts that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, eight have given a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $10.44.

Several equities analysts have recently commented on the stock. Weiss Ratings raised shares of CAMP4 Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, October 16th. Cantor Fitzgerald reissued an “overweight” rating on shares of CAMP4 Therapeutics in a report on Tuesday, September 29th. Zacks Research upgraded shares of CAMP4 Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, August 17th. Chardan Capital cut their target price on CAMP4 Therapeutics from $6.50 to $6.00 and set a “buy” rating on the stock in a research note on Tuesday, September 29th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $15.00 target price (up from $12.00) on shares of CAMP4 Therapeutics in a research report on Friday, August 14th.

CAMP4 Therapeutics Stock Performance

Shares of CAMP opened at $3.30 on Friday. The stock has a 50-day moving average price of $3.99 and a 200 day moving average price of $4.13. CAMP4 Therapeutics has a one year low of $2.90 and a one year high of $7.75. The company has a market capitalization of $207.08 million, a P/E ratio of -1.42 and a beta of 0.27.

CAMP4 Therapeutics (NASDAQ:CAMP) last released its earnings results on Thursday, August 13th. The Wireless communications provider reported ($0.58) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.34). The business had revenue of $1.78 million for the quarter. CAMP4 Therapeutics had a negative net margin of 2,543.74% and a negative return on equity of 252.79%. As a group, equities research analysts forecast that CAMP4 Therapeutics will post -0.66 earnings per share for the current fiscal year.

Insider Activity at CAMP4 Therapeutics

In other CAMP4 Therapeutics news, Director Andrew J. Schwab sold 400,000 shares of CAMP4 Therapeutics stock in a transaction that occurred on Thursday, August 27th. The shares were sold at an average price of $4.04, for a total value of $1,616,000.00. Following the transaction, the director owned 2,033,270 shares in the company, valued at approximately $8,214,410.80. The trade was a 16.44% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO Kelly Gold bought 10,000 shares of the firm’s stock in a transaction that occurred on Monday, August 31st. The stock was bought at an average price of $3.96 per share, for a total transaction of $39,600.00. Following the completion of the acquisition, the chief financial officer directly owned 10,000 shares in the company, valued at approximately $39,600. The trade was a ? increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last 90 days, insiders bought 46,031 shares of company stock valued at $99,051 and sold 593,613 shares valued at $2,504,037. Company insiders own 21.69% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Bank of America Corp DE purchased a new position in CAMP4 Therapeutics during the 2nd quarter worth approximately $78,000. Deutsche Bank AG bought a new position in CAMP4 Therapeutics during the second quarter valued at about $138,000. Bank of New York Mellon Corp acquired a new stake in CAMP4 Therapeutics in the 2nd quarter worth approximately $365,000. SummitTX Capital L.P. acquired a new stake in shares of CAMP4 Therapeutics in the first quarter worth $1,497,000. Finally, BlackRock Inc. acquired a new position in CAMP4 Therapeutics during the 2nd quarter worth $7,185,000.

About CAMP4 Therapeutics

CAMP4 Therapeutics Corporation is a clinical-stage biotechnology company focused on developing medicines that increase the production of disease-relevant proteins by activating the expression of specific genes. The company’s approach is designed to address diseases caused by insufficient protein levels, including certain genetic disorders in which boosting activity from a functional gene copy may provide therapeutic benefit.

CAMP4 uses its Regulatory Action Platform, or RAP, to identify regulatory elements that control RNA production and discover small-molecule compounds capable of increasing the expression of selected genes.